StreetInsider.com News Articles

Form 4 NEOGENOMICS INC For: Jun 15 Filed by: TETRAULT LYNN A.

Wed, 17 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260617/26659926.html

Form 4 NEOGENOMICS INC For: Jun 15 Filed by: TETRAULT LYNN A.

Wed, 17 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260617/26659926.html

Form 8-K NEOGENOMICS INC For: Jun 17

Wed, 17 Jun 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26656460.html

Form 8-K NEOGENOMICS INC For: Jun 17

Wed, 17 Jun 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260617/26656460.html

NeoGenomics prices $275 million convertible notes due 2032

Wed, 17 Jun 2026 06:00:31 -0400

NeoGenomics, Inc. (NASDAQ: NEO) has priced a private offering of $275 million in aggregate principal amount of 0.75% convertible senior notes due 2032, with an option granted to initial purchasers to buy up to an additional $41.25 million in notes. The offering is expected to close on June 22, 2026, subject to customary closing conditions.

The notes will mature on July 1, 2032, bearing interest at 0.75% per year, payable semiannually beginning January 1, 2027. The initial conversion rate is 70.6140 shares of common stock per $1,000 principal amount, representing a conversion price of approximately $14.16 per share — a 35%

NeoGenomics prices $275 million convertible notes due 2032

Wed, 17 Jun 2026 06:00:31 -0400

NeoGenomics prices $275 million convertible notes due 2032

Wed, 17 Jun 2026 06:00:31 -0400

NeoGenomics prices $275 million convertible notes due 2032

Wed, 17 Jun 2026 06:00:31 -0400

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

Wed, 17 Jun 2026 06:00:00 -0400

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate principal amount of 0.75% convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

Wed, 17 Jun 2026 06:00:00 -0400

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

Wed, 17 Jun 2026 06:00:00 -0400

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

Wed, 17 Jun 2026 06:00:00 -0400

Form 8-K NEOGENOMICS INC For: Jun 15

Mon, 15 Jun 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260615/26648696.html

Form 8-K NEOGENOMICS INC For: Jun 15

Mon, 15 Jun 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260615/26648696.html

NeoGenomics proposes $275M convertible senior notes due 2032

Mon, 15 Jun 2026 17:24:14 -0400

NeoGenomics, Inc. (NASDAQ: NEO) announced a private offering of $275 million in convertible senior notes due 2032, targeting qualified institutional buyers under Rule 144A of the Securities Act of 1933.

The Fort Myers, Florida-based cancer diagnostics company said it expects to grant initial purchasers an option to buy up to an additional $41.25 million in aggregate principal amount of the notes within a 13-day period following the initial issuance date.

The notes will be senior, unsecured obligations maturing July 1, 2032, with interest paid semi-annually. NeoGenomics may redeem the notes in whole or in part on or after July 6, 2029, if

NeoGenomics proposes $275M convertible senior notes due 2032

Mon, 15 Jun 2026 17:24:14 -0400

The notes will be senior, unsecured obligations maturing July 1, 2032, with interest paid semi-annually. NeoGenomics may redeem the notes in whole or in part on or after July 6, 2029, if

NeoGenomics proposes $275M convertible senior notes due 2032

Mon, 15 Jun 2026 17:24:14 -0400

The notes will be senior, unsecured obligations maturing July 1, 2032, with interest paid semi-annually. NeoGenomics may redeem the notes in whole or in part on or after July 6, 2029, if

NeoGenomics proposes $275M convertible senior notes due 2032

Mon, 15 Jun 2026 17:24:14 -0400

The notes will be senior, unsecured obligations maturing July 1, 2032, with interest paid semi-annually. NeoGenomics may redeem the notes in whole or in part on or after July 6, 2029, if

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

Mon, 15 Jun 2026 17:24:00 -0400

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, NeoGenomics expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

Mon, 15 Jun 2026 17:24:00 -0400

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, NeoGenomics expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

Mon, 15 Jun 2026 17:24:00 -0400

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, NeoGenomics expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

Mon, 15 Jun 2026 17:24:00 -0400

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with this offering, NeoGenomics expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date

Form 144 NEOGENOMICS INC Filed by: TETRAULT LYNN A.

Mon, 15 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260615/26647989.html

Form 144 NEOGENOMICS INC Filed by: TETRAULT LYNN A.

Mon, 15 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260615/26647989.html

Form 4 NEOGENOMICS INC For: Jun 09 Filed by: TETRAULT LYNN A.

Thu, 11 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260611/26635739.html